Department of Pharmacy, University Medical Center of the Johannes Gutenberg University, Mainz, Rheinland-Pfalz, Germany
Department of Pharmacy, University Medical Center of the Johannes Gutenberg University, Mainz, Rheinland-Pfalz, Germany.
Eur J Hosp Pharm. 2023 Jan;30(1):11-16. doi: 10.1136/ejhpharm-2020-002597. Epub 2021 May 5.
The aim of this study was to determine and compare the physicochemical stability of two carmustine-containing medicinal products licensed and marketed in Europe as Carmustin Obvius (Medac GmbH) and Carmubris (Tillomed Pharma GmbH). Reconstituted stock solutions and diluted ready-to-administer infusion solutions of the two products were investigated.
Reconstituted carmustine stock solutions (3.3 mg/mL) and ready-to-administer infusion solutions (0.2 mg/mL, 1.0 mg/mL) prepared in prefilled 5% glucose injection solution PP/PE bags were stored at 22°C or 2-8°C over a maximum period of 66 hours protected from light. Samples were taken immediately after reconstitution or dilution and after 3.5, 6, 8.5 and 11 hours when stored at 22°C or after (12), 24, 48 and 60 hours when stored at 2-8°C, followed by 3- and 6-hour storage at 22°C (60+3 hours, 60+6 hours). Physicochemical stability was determined by reversed-phase high-performance liquid chromatography with UV detection, measurement of pH, osmolarity and inspection for visible particles or colour changes.
Carmustin Obvius and Carmubris reconstituted stock solutions were physicochemically stable for at least 48 hours when stored at 2-8°C. Carmustin Obvius and Carmubris infusion solutions 0.2 mg/mL were physicochemically stable for at least 8.5 hours and 60 hours when stored at 22°C and 2-8°C, respectively. After subsequent storage of the 60-hour refrigerated test solutions for 3 hours at 22°C, the carmustine concentrations averaged the 90% limit and fell below the 90% limit after 6 hours. Carmustin Obvius infusion solutions 1.0 mg/mL were physicochemically stable for at least 8.5 hours when stored at 22°C and for 60 hours when stored at 2-8°C.
According to the physicochemical stability data, the shelf life (95% limit) of the refrigerated stock solutions is 48 hours and the shelf life (90% limit) of ready-to-administer infusion solutions (0.2 mg/mL, 1.0 mg/mL) is 60 hours at 2-8°C or 8.5 hours at 22°C under light protection. These results facilitate the use of both medicinal products in a pharmacy-based centralised cytotoxic preparation unit.
本研究旨在确定并比较两种在欧洲获得许可和上市的含卡莫司汀的药物的理化稳定性,这两种药物分别为 Carmustin Obvius(Medac GmbH)和 Carmubris(Tillomed Pharma GmbH)。研究了两种产品的重组原料药溶液和稀释后的即用型输注溶液。
将两种产品的重组卡莫司汀原料药溶液(3.3mg/mL)和即用型输注溶液(0.2mg/mL、1.0mg/mL)在预填充的 5%葡萄糖注射液 PP/PE 袋中制备,在 22°C 或 2-8°C 下避光保存,最长 66 小时。在重组或稀释后立即以及在 22°C 下储存 3.5、6、8.5 和 11 小时,或在 2-8°C 下储存(12)、24、48 和 60 小时后,随后在 22°C 下再储存 3 和 6 小时(60+3 小时,60+6 小时)时,分别取样。通过反相高效液相色谱法结合紫外检测、pH 值、渗透压和可见颗粒或颜色变化的测定来确定理化稳定性。
当在 2-8°C 下储存时,Carmustin Obvius 和 Carmubris 的重组原料药溶液至少稳定 48 小时。Carmustin Obvius 和 Carmubris 的输注溶液 0.2mg/mL 在 22°C 和 2-8°C 下分别至少稳定 8.5 小时和 60 小时。冷藏测试溶液在 22°C 下随后储存 3 小时后,卡莫司汀浓度平均达到 90%的限度,并在 6 小时后低于 90%的限度。当在 22°C 下储存时,Carmustin Obvius 的输注溶液 1.0mg/mL 至少稳定 8.5 小时,当在 2-8°C 下储存时至少稳定 60 小时。
根据理化稳定性数据,冷藏原料药溶液的有效期(95%限度)为 48 小时,即用型输注溶液(0.2mg/mL、1.0mg/mL)的有效期(90%限度)在 2-8°C 下为 60 小时,在 22°C 下避光保护下为 8.5 小时。这些结果为在基于药房的集中细胞毒性制备单元中使用这两种药物提供了便利。